

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Valdecoxib-d₃ Item No. 28699

CAS Registry No.: 1219794-90-7

Formal Name: 4-(5-(methyl-d₃)-3-phenylisoxazol-4-yl)

benzenesulfonamide

MF: $C_{16}H_{11}D_3N_2O_3S$


FW: 317.4

Chemical Purity: ≥98% (Valdecoxib)

Deuterium

Incorporation: \geq 99% deuterated forms (d₁-d₃); \leq 1% d₀

Supplied as: A solid Storage: -20°C Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Valdecoxib-d3 is intended for use as an internal standard for the quantification of valdecoxib (Item No. 10006120) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Valdecoxib-d₃ is supplied as a solid. A stock solution may be made by dissolving the valdecoxib-d₃ in the solvent of choice, which should be purged with an inert gas. Valdecoxib-d3 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of valdecoxib-d₃ in ethanol is approximately 5 mg/ml and approximately 20 mg/ml in DMSO and DMF.

Description

Valdecoxib is a selective inhibitor of COX-2 (IC_{50} s = 0.005 and 140 μ M, for human recombinant COX-2 and COX-1, respectively). It decreases LPS-induced production of prostaglandin E2 (PGE2; Item No. 14010) in isolated human whole blood (IC_{50} = 0.89 μ M). Valdecoxib reduces carrageenan-induced paw edema and adjuvant-induced arthritis in rats (ED_{50} s = 10.2 and 0.032 mg/kg, respectively).

Reference

1. Talley, J.J., Brown, D.L., Carter, J.S., et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J. Med. Chem. 43(5), 775-777 (2000).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 09/12/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM